Previous, the STAMPEDE trial has shown that, among men with locally advanced or metastatic prostate cancer, ADT plus abiraterone and prednisolone was associated with significantly higher rates of overall and failure-free survival than ADT alone [1]. Now, long-term outcomes in subset of patients in STAMPEDE who had metastatic disease (M1) at the start of the treatment were presented [2].
Of 1,917 enrolled patients, 1,003 (52%) had M1 disease. They were 1:1 randomised to receive ADT versus ADT plus abiraterone (1,000 mg daily) plus prednisolone (5 mg daily). At a median follow-up of 6.1 years, median overall survival (OS) in the abiraterone arm was 6.6 years versus 3.8 years in the control arm (HR 0.60; P<0.00001). Median failure-free survival (including PSA failure) was 4.3 versus 0.96 years (HR 0.34; P< 0.00001). In line with these findings, median progression-free survival (PFS), metastatic PFS, and skeletal-related events were in favour of treatment with abiraterone (HR 0.58, HR 0.60, and HR 0.56, respectively). The relative effect of abiraterone was similar in low-burden and high-burden patients.
- James ND, et al. N Engl J Med 2017;377:338-351.
- James ND, et al. Abiraterone acetate plus prednisolone for hormone-naïve prostate cancer (PCa): Long-term results from metastatic (M1) patients in the STAMPEDE randomised trial (NCT00268476). ESMO 2020 Virtual Meeting, abstract 611O.
Posted on
Previous Article
« New treatment option for patients with mCRPC Next Article
Immuno-combination therapy in metastatic melanoma »
« New treatment option for patients with mCRPC Next Article
Immuno-combination therapy in metastatic melanoma »
Table of Contents: ESMO 2020
Featured articles
COVID-19 and Cancer
Breast Cancer
Gastrointestinal Cancers
Lung Cancer
Melanoma
Genitourinary Cancers
Bladder cancer risk and early detection
Gynaecological Cancers
Basic Science
Related Articles
November 25, 2020
PD-L1 density, a new predictive biomarker in NSCLC
November 25, 2020
First-line treatment of advanced/metastatic RCC
November 25, 2020
Treatment of recurrent ovarian cancer
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy